Having trouble accessing articles? Reset your cache.

Androxal enclomiphene: Phase III data

Top-line data from 151 men with secondary hypogonadism in the intent-to-treat (ITT) population of the double-blind, U.S. Phase III ZA-301 trial showed that once-daily oral Androxal met the co-primary endpoints of >=75% of patients achieving a 24-hour average testosterone level within the normal range (300-1,040 ng/dL) at week 12 (79% achieved the threshold) and non-inferiority to placebo at a

Read the full 599 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers